Navigation Links
Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis
Date:2/2/2009

HAWTHORNE, N.Y., February 2, 2009 Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) on January 30, 2009 for Fampridine-SR, a novel therapy being developed to improve walking ability in people with multiple sclerosis (MS). The Company expects that the NDA filing, if accepted, will be subject to standard review, which would provide a target for the FDA to complete its review within ten months from receipt of the submission.

"This NDA filing is a major milestone for Acorda and our Fampridine-SR development program," said Acorda Therapeutics President and CEO Ron Cohen, M.D. "Walking impairment is one of the most pervasive and alarming aspects of MS for patients, their families and their health care providers. There are no medicines currently indicated to improve walking ability in people with MS, and Fampridine-SR therefore may represent an important new approach to MS therapy. We are excited to have taken this major step toward potentially making Fampridine-SR available to help people with MS."

Approximately 400,000-500,000 people in the Unites States have MS, and recent studies indicate that between 64-85% of people with MS have walking disability1,2. Fully 70% of people with MS who have walking disability report it to be the most challenging aspect of their disease1.

The Fampridine-SR NDA submission is based on data from a comprehensive development program assessing the safety and efficacy of Fampridine-SR, including two Phase 3 trials that involved 540 people with MS and were conducted under Special Protocol Assessments (SPAs) from the FDA. The safety and efficacy profile of Fampridine-SR was consistent across Phase 2 and Phase 3 trials. Overall, the NDA filing included more that 50 clinical studies of Fampridine-SR. The total exposure to Fampridine-SR in MS studies filed as part of the NDA was over 1,20
'/>"/>

Contact: Jeff MacDonald
jmacdonald@acorda.com
914-347-4300
Ruder Finn Public Relations
Source:Eurekalert

Page: 1 2

Related biology news :

1. A novel target for therapeutics against Staph infection
2. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
3. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
4. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
5. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
6. CU-Boulder, biotech firm team up on python project in search for human cardiac therapeutics
7. Michael J. Fox Foundation PD Therapeutics Conference
8. Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
9. ORNL supercomputer simulation wins prize for fastest-running science application
10. Track your fitness, environmental impact with new cell phone applications
11. New filtering technology has environmental, industrial applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... is developing drugs that are highly effective against a ... patient. Such properties are directly related to the 3D ... have a shape that is perfectly complementary to a ... specificity. Publishing in Nature Chemistry , EPFL scientists ... the 3D structure of bioactive peptides and enhance their ...
(Date:8/31/2014)... MA -- Over the past several decades, malaria diagnosis has ... patient, a technician smears the blood across a glass slide, ... microscope for the Plasmodium parasite, which causes the disease. This ... in the blood an important measure of disease severity ... human error. , A research team from the Singapore-MIT Alliance ...
(Date:8/29/2014)... has been known about what genetic changes transform wild ... one of whom is a University of Montana assistant ... controlling the development of the brain and the nervous ... was published Aug. 28 in Science and ... at http://www.sciencemag.org/ ., The domestication of animals and ...
Breaking Biology News(10 mins):A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3A new way to diagnose malaria 2A new way to diagnose malaria 3New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... 2012Mary Ann Liebert, Inc., publishers announces the launch ... the science and engineering of soft materials in mobile machines. ... the urgent need for research on robotic technology that can ... or human-built environments. Soft Robotics will be published ...
... high potential to treat Ewing sarcoma, an often deadly cancer ... behind it, come hand-in-hand in a new study by researchers ... The report appears in today,s online issue of the journal ... caused by a cancer-causing protein called EWS/FLI," said Stephen Lessnick, ...
... increases the risk of melancholic depressive symptoms, according to ... subjects. On the other hand, non-melancholic depressive symptoms are ... Based on these new observations, melancholic and non-melancholic depression ... terms of proinflammation and diet. The study was the ...
Cached Biology News:'Soft Robotics': A groundbreaking new journal on engineered soft devices that Interact with Living Systems 2Possible new treatment for Ewing sarcoma 2Lack of nutrients and metabolic syndrome linked to different subtypes of depression 2
(Date:8/29/2014)... (PRWEB) August 29, 2014 According to a ... Market” the global orthobiologics market was valued at USD 3,754.6 ... worth USD 5,519.9million in 2019at a CAGR of 5.9% from ... 50 years and above is afflicted by bone and joint ... the year 2020. This has and will continue to increase ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... reported financial results for the six months ended ... expressed in Canadian dollars and presented under International ... 2014 Highlights , Announced top-line results ... primary endpoint for subjects enrolled in the Phase ...
(Date:8/29/2014)... Livermore, California (PRWEB) August 29, 2014 ... Department of Energy's 2014 Hydrogen Production R&D ... photoelectrochemically -- by splitting water using sunlight. , ... Laboratory (NREL) and the University of Nevada, Las ... its work developing models of photoelectrochemical solar-hydrogen production ...
(Date:8/29/2014)... 2014 A major challenge before new ... dense realm of Boston-Cambridge, is gaining visibility that can ... Sherley, the Director of Boston’s Adult Stem Cell Technology ... national visibility of his company an important priority since ... addition to a social media marketing campaign ...
Breaking Biology Technology:Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Livermore Team Awarded for Hydrogen Production Research 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4
... 2011 Sangui enters commercialization phase / Initial ... State of Tamaulipas has issued an initial order of Hemo2Spray, ... wound debridement product Scabremove both registered by the Mexican authorities ... order of the wound spray and Sangui management is positive ...
... and myeloma are both malignant diseases that arise from ... lymph nodes and the bone marrow. Although considerable progress ... they remain a significant challenge for patients and their ... for lymphoma and myeloma will be presented today at ...
... Corp. (NASDAQ: BSTC ), a biopharmaceutical company ... ® in the U.S. and XIAPEX ® ... George Gould, Esq., to its Board of Directors effective ... of George M. Gould, LLC, and of counsel to ...
Cached Biology Technology:Mexican State of Tamaulipas Starts Training Doctors in Sangui Wound Management 2Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 2Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 3Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 4Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 5Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 6Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 7Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 8Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 9BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 2BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 3BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 4
TGF-beta 1,-2,-3 MAb (Clone 1D11)...
Request Info...
Mouse monoclonal [B314.1 (MAC 387)] to Macrophage L1 protein Calprotectin (rating: ****) ( Abpromise for all tested applications)....
Human/Mouse/Rat AMPK beta 1 Affinity Purified Polyclonal Ab...
Biology Products: